Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc to Discuss FDA Approval for VOXZOGO™ Call Transcript

Nov 19, 2021 / 04:30PM GMT
Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Please go ahead, JJ.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Okay. So welcome, everyone, and thank you for joining us on today's call. We are, as you can imagine, very pleased to share the news of FDA's approval of VOXZOGO for children, ages 5 and older. I want to thank the FDA, the families who participated in our cable programs, our investigators and advocates and especially my colleagues in clinical development and regulatory affairs at BioMarin who have all contributed to this important day for children with achondroplasia. VOXZOGO's approval in Europe in August and in the United States today marks a significant milestone for BioMarin. The teams have shown tremendous persistence and diligence with a single-mind focus on getting VOXZOGO approved for the benefits of families seeking a treatment option for achondroplasia. Perseverance is part of our company's culture, and it is achievers like today's that today's approval of VOXZOGO that keeps us motivated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot